DAPK1 and early-onset autosomal dominant Alzheimer disease: Accordingly, numerous genetic and pharmacological DAPK1-targeting approaches have demonstrated neuroprotective and synapto-protective benefits in animal models of stroke, excitotoxicity, Alzheimer’s disease, Parkinson’s disease, and chronic stress (Li et al., 2018; Kim et al., 2019; Su et al., 2019).